Souhaitez-vous accéder aux communiqués récents ?

Healis Therapeutics opens IND, enabling first U.S. trials for Depression, PTSD, and neuropsychiatric disorders

VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Ahead of the official opening of AGC Biologics’ Yokohama site, a customer has already secured half of the facility’s manufacturing capacity.

FORT LEE, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- via InvestorWire -- Moody Capital Solutions (“Moody Capital”), a relationship-driven investment bank committed to delivering high-touch, high-quality...

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease.

MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema

Dublin, July 23, 2026 (GLOBE NEWSWIRE) -- The "Licensing Deals in Pharmaceuticals 2020-2026" has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the report includes...

RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO) dedicated to strengthening the nation's...